{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:45:34Z","timestamp":1747154734921,"version":"3.40.5"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ajp.2024.104011","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T08:57:36Z","timestamp":1710838656000},"page":"104011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Look at DAYBUE\u2122 (Trofinetide) as first ever drug for treatment of Rett Syndrome"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3483-6111","authenticated-orcid":false,"given":"Muiz Khan","family":"Tareen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zayed","family":"Mohiyuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajp.2024.104011_bib1","unstructured":"021164s000lbl.pdf. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021164s000lbl.pdf\u200b. (Accessed 27 February 2024)."},{"key":"10.1016\/j.ajp.2024.104011_bib2","unstructured":"217026s000lbl.pdf. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217026s000lbl.pdf (Accessed 18 October 2023)."},{"key":"10.1016\/j.ajp.2024.104011_bib3","unstructured":"DAYBUE: FDA Approved Rett Syndrome Treatment | Acadia Pharmaceuticals. (Accessed 18 October 2023). https:\/\/acadia.com\/our-medicines\/daybue\/."},{"key":"10.1016\/j.ajp.2024.104011_bib4","unstructured":"Daybue (trofinetide) | CenterWatch. (Accessed 18 October 2023)https:\/\/www.centerwatch.com\/directories\/1067-fda-approved-drugs\/listing\/4848-daybue-trofinetide."},{"key":"10.1016\/j.ajp.2024.104011_bib5","unstructured":"FDA Approves First Oral Treatment for Postpartum Depression. (Accessed 27 February 2024)https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-treatment-postpartum-depression."},{"key":"10.1016\/j.ajp.2024.104011_bib6","unstructured":"FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause. Accessed 27 February 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause."},{"key":"10.1016\/j.ajp.2024.104011_bib7","unstructured":"FDA GrantsAccelerated Approval for Alzheimer\u2019s Disease Treatment. Accessed 27 February 2024, https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-disease-treatment."},{"key":"10.1016\/j.ajp.2024.104011_bib8","unstructured":"First drug for Rett syndrome tested at UAB. Accessed 18 October 2023. https:\/\/www.uab.edu\/news\/research\/item\/13512-first-drug-for-rett-syndrome-tested-at-uab."},{"issue":"16","key":"10.1016\/j.ajp.2024.104011_bib9","doi-asserted-by":"crossref","first-page":"e1912","DOI":"10.1212\/WNL.0000000000007316","article-title":"Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome","volume":"92","author":"Glaze","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ajp.2024.104011_bib10","unstructured":"Pfizer\u2019s ZAVZPRET\u2122 (zavegepant) Migraine Nasal Spray Receives FDA Approval.https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-zavzprettm-zavegepant-migraine-nasal-spray.\u00a0(Accessed 27 February 2024)."}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201824001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201824001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T10:41:48Z","timestamp":1715251308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201824001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":10,"alternative-id":["S1876201824001047"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2024.104011","relation":{},"ISSN":["1876-2018"],"issn-type":[{"type":"print","value":"1876-2018"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Look at DAYBUE\u2122 (Trofinetide) as first ever drug for treatment of Rett Syndrome","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2024.104011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104011"}}